
The Centers for Medicare and Medicaid Services (CMS) has officially named the first 10 drugs chosen for price negotiation under the Inflation Reduction Act (IRA), and while most picks were anticipated, a few of the medicines named on Tuesday came as something of a surprise. The IRA was highly specific with which Medicare-covered drugs could be eligible for negotiation, as well as which ones could not. In order to be up for selection, the drugs had to be approved by the the Food and Drug Administration for at least seven...